Acute Promyelocytic Leukemia (apl) Therapeutics
1. Trisenox patent expiration
Treatment: In combination with tretinoin, treating adults and pediatric patients 1 year and older with newly-diagnosed low-risk acute promyelocytic leukemia (apl) characterized by the presence of the t(15; 17) t...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6982096 | CEPHALON | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
Nov, 2018
(7 years ago) | |
| US8273379 | CEPHALON | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
Nov, 2018
(7 years ago) | |
| US6855339 | CEPHALON | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
Nov, 2018
(7 years ago) | |
| US6884439 | CEPHALON | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
Nov, 2018
(7 years ago) | |
| US6723351 | CEPHALON | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
Nov, 2018
(7 years ago) | |
| US6861076 | CEPHALON | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
Nov, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-167) | Jan 12, 2025 |
Drugs and Companies using ARSENIC TRIOXIDE ingredient
Market Authorisation Date: 25 September, 2000
Dosage: INJECTABLE
How can I launch a generic of TRISENOX before it's drug patent expiration?
More Information on Dosage
TRISENOX family patents
